Active immunization against measles, mumps and rubella of children after 9 months of age, adolescents and adults.
Composition:
1 dose (0.5 ml) contains live attenuated measles viruses (Schwarz strain), mumps viruses (strain RIT 4385) and rubella viruses (strain Wistar RA 27/3).
Action:
Vaccine for simultaneous immunization against measles, mumps and rubella. It contains live attenuated viruses obtained from chicken embryo tissue culture (mumps and measles viruses) and human diploid cells (rubella viruses). The presence of measles antibodies was found in 98%, against mumps in 96.1%, and against rubella in 99.3% of vaccinated, previously seronegative individuals.
Contraindications:
Hypersensitivity to neomycin or other components of the vaccine (contact dermatitis caused by neomycin is not a contraindication to vaccination). Allergy to egg white. acute and severe illness with fever. Disturbed immune system response (primary and secondary immunodeficiency). Pregnancy (pregnancy should be avoided within 3 months of inoculation).
Precautions:
The vaccine can not be administered intravascularly under any circumstances. Limited measles protection may be achieved after using the vaccine up to 72 hours after contact with a measles patient. Infants vaccinated in the 1st year of age may not produce a sufficient immune response to the components of the vaccine due to the possible presence of maternal antibodies in the body. Caution should be exercised in people with OA disorders who are at risk of febrile seizures or family history of seizures and in patients with a history of a history of allergies or a history of a family history. Special care should be taken in patients with anaphylactic, anaphylactoid or other immediate-type reactions (eg generalized urticaria, edema of the mouth and throat, difficulty in breathing, hypotension or shock) after ingestion of eggs. In patients with thrombocytopenia after the first dose of the vaccine, cases of exacerbation or recurrence have been reported, therefore the benefit-risk ratio of vaccination should be carefully assessed. Patients with rare hereditary fructose intolerance should not be vaccinated because of the content in the sorbitol vaccine.
Pregnancy and lactation:
Administration of the vaccine is contraindicated during pregnancy. Pregnancy should be prevented for 1 month after vaccination. There are only limited data on the use of the vaccine in breast-feeding women. Studies have shown that breast-feeding women who are vaccinated with a live at least approved rubella vaccine can secrete viruses and milk and transfer them to a breastfed child without evidence of clinical signs of disease. Immunization should only be carried out in cases where the benefits outweigh the potential risks.
Side effects:
Very common: redness at the injection site, fever (measured in the rectum ≥38st.C, measured under the armpit or in the mouth ≥37,5 ° C). Common: upper respiratory tract infection, rash, pain and swelling at the injection site, fever (measured in the rectum> 39.5 ° C, measured under the armpit or in the mouth> 39 ° C). Uncommon: otitis media, generalized enlargement of the lymph nodes, anorexia, nervousness, insomnia, unusual crying, conjunctivitis, bronchitis, cough, diarrhea, vomiting, parotid gland swelling. Rare: allergic reactions, febrile seizures. The frequency categories for adverse reactions were similar after the first and second doses of vaccine, with the exception of pain at the injection site, which often occurred after the first dose of the vaccine and very often after the second dose of the vaccine. Post-marketing adverse reactions: meningitis, testicular and epididymitis, atypical mild or weak measles or mumps-like symptoms, thrombocytopenia, thrombocytopenic purpura, anaphylactic reactions, transverse myelitis, Guillain-Barre syndrome,peripheral neuritis, encephalitis, erythema multiforme, arthralgia, arthritis, Kawasaki disease.
Dosage:
Subcutaneously or intramuscularly. The vaccination scheme used should be consistent with the Protective Vaccine Program. It is recommended to administer the vaccine at the earliest 9 months of age. Infants in one year of age may not sufficiently respond to the vaccine. However, if the epidemiological situation requires the vaccination of infants in the first year (eg outbreaks or travel to endemic areas), a second dose of vaccine is recommended in 2 years, preferably 3 months after the first dose (period between doses should not be shorter than 4 weeks). It can also be used as a booster vaccination also for those who have previously been vaccinated with other combined measles, mumps and rubella vaccines.
(C)
